Drug maker Eli Lilly & Co. says an article in The New York Times contained only a small fraction of a company statement that claimed the paper was using selected internal memos out of context.
Lilly and the Times have been waging a public relations battle since Dec. 16, when the Times began publishing stories alleging Lilly played down safety data on their lead drug, the anti-psychotic medication Zyprexa. The stories are based on confidential documents obtained by the Times through a lawyer representing mentally ill patients, who had subpoenaed the documents.
